Despite heterogeneous patient characteristics, compromising to some degree the comparison with published trial data, the present retrospective data analyses are indicative for a treatment-specific activity profile of the novel biomodulatory therapy approach: Outcome of the chosen biomodulatory therapy turned out to be significantly dependent on ECOG status, CLIP score, maximum diameter of the largest tumor, preceding tumor surgery, CRP and AFP concentrations in serum at study inclusion. This evidence concerns the gene CRP and neoplasm.